A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
Фаза 4
Завершено
NCT03641560
| Заболевание | Metastatic Castration Resistant Prostate Cancer |
|---|
| Фаза | Фаза 4 |
|---|
| Спонсор | Astellas Pharma Inc |
|---|
| Статус | Завершено |
|---|
| Участники | 52 участн. |
|---|
| Вмешательство | Enzalutamide, Androgen deprivation therapy (ADT) |
|---|
| Дата начала | 19.09.2018 |
|---|
| Дата завершения | 20.02.2024 |
|---|
| Публикация результатов | 23.01.2025 |
|---|
Кратко
The purpose of this study was to evaluate the safety and tolerability of enzalutamide in Indian patients with progressive mCRPC previously treated with docetaxel-based chemotherapy. This study also evaluated the effect of enzalutamide on prostate-specific antigen (PSA).
Number of Participants With Treatment- Emergent Adverse Events (TEAEs)
From first dose of study drug until 30 days after last dose (Up to 1899 days) · Participants
| Enzalutamide | 36 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.